Cardiff Oncology Inc (FRA:XE7C)

€ 2.8 0.1 (3.7%) Market Cap: 150.33 Mil Enterprise Value: 95.75 Mil PE Ratio: 0 PB Ratio: 3.01 GF Score: 59/100

Q2 2024 Cardiff Oncology Inc Earnings Call Transcript
Aug 08, 2024

€1.88 (-5.54%)

Earnings
Q1 2024 Cardiff Oncology Inc Earnings Call Transcript
May 02, 2024

€3.87 (-5.39%)

Earnings
Q4 2023 Cardiff Oncology Inc Earnings Call Transcript
Feb 29, 2024

€1.64 (+2.24%)

Earnings
Q3 2023 Cardiff Oncology Inc Earnings Call Transcript
Nov 02, 2023

€1.01 (+2.44%)

Earnings
Cardiff Oncology Inc Clinical Update Call Transcript
Sep 26, 2023
Cardiff Oncology Inc Clinical and Corporate Update Call Transcript
Aug 07, 2023
Cardiff Oncology Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Cardiff Oncology Inc at Cowen Health Care Conference- GI/GU Oncology Panel Transcript
Mar 07, 2023
Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) Transcript
Dec 07, 2022
Cardiff Oncology Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Cardiff Oncology Inc to Provide a Clinical and Corporate Update Call Transcript
Sep 12, 2022
Cardiff Oncology Inc to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer at ASCO-GI Transcript
Jan 18, 2022
Cardiff Oncology Inc to Discuss New Data from Lead Clinical Program in KRAS-mutated mCRC Webinar Transcript
Sep 08, 2021
Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Cardiff Oncology Inc KOL Webinar Transcript
Apr 12, 2021
Cardiff Oncology Inc Discusses KRAS Mutations in Cancer Transcript
Oct 14, 2020
Cardiff Oncology, Inc. - Special Call Transcript
Sep 23, 2020
Cardiff Oncology Inc Onvansertib Clinical Trials Transcript
May 18, 2020
Trovagene Inc at Needham Healthcare Conference Transcript
Apr 15, 2020
Trovagene Inc Business Update Conference Call Transcript
Jun 07, 2019

Cardiff Oncology Inc Clinical and Corporate Update Call Transcript

Aug 07, 2023 / 09:00PM GMT

Release Date Price: €1.45 (-5.59%)

Transcript 8-K10-Q

Operator

Welcome to the Cardiff Oncology conference call to discuss the company's mCRC program update and development plan. (Operator Instructions) As a reminder, this call is being recorded today, Monday, August 7, 2023. I would now like to turn the conference call over to Laurence Watts of Gilmartin Group. Please go ahead.

Laurence Watts

Gilmartin Group LLC - IR

Thank you, operator. Slides for today's investor call can be found on the homepage and the events and presentations tab of the Cardiff Oncology-website at www.cardiffoncology.com. Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander; Chief Medical Officer, Fairooz Kabbinavar; Chief Scientific Officer, Tod Smeal; Chief Financial Officer, Jamie Levine; and Senior Vice President of Regulatory Affairs, Charles Monahan.

Please turn to Slide 2. During this conference call, management will make forward-looking statements, including, without limitation, statements related to guidance, results, and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.